AFS Financial Group LLC Sells 9,143 Shares of Merck & Co., Inc. (NYSE:MRK)

AFS Financial Group LLC cut its stake in Merck & Co., Inc. (NYSE:MRKFree Report) by 57.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 6,875 shares of the company’s stock after selling 9,143 shares during the quarter. Merck & Co., Inc. accounts for 0.7% of AFS Financial Group LLC’s holdings, making the stock its 21st biggest position. AFS Financial Group LLC’s holdings in Merck & Co., Inc. were worth $750,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently modified their holdings of MRK. Ruedi Wealth Management Inc. boosted its holdings in shares of Merck & Co., Inc. by 180.2% in the 3rd quarter. Ruedi Wealth Management Inc. now owns 311 shares of the company’s stock valued at $32,000 after buying an additional 200 shares during the last quarter. AlphaMark Advisors LLC acquired a new stake in shares of Merck & Co., Inc. in the 4th quarter valued at approximately $34,000. Valued Wealth Advisors LLC acquired a new stake in shares of Merck & Co., Inc. in the 4th quarter valued at approximately $42,000. TFO Wealth Partners LLC boosted its holdings in shares of Merck & Co., Inc. by 108.1% in the 3rd quarter. TFO Wealth Partners LLC now owns 464 shares of the company’s stock valued at $48,000 after buying an additional 241 shares during the last quarter. Finally, Ameliora Wealth Management Ltd. acquired a new stake in shares of Merck & Co., Inc. in the 3rd quarter valued at approximately $50,000. 76.07% of the stock is owned by institutional investors.

Insider Activity at Merck & Co., Inc.

In other news, EVP Steven Mizell sold 50,694 shares of the company’s stock in a transaction dated Friday, February 2nd. The stock was sold at an average price of $126.65, for a total value of $6,420,395.10. Following the completion of the transaction, the executive vice president now directly owns 23,619 shares in the company, valued at approximately $2,991,346.35. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, insider Joseph Romanelli sold 1,000 shares of the stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $124.89, for a total transaction of $124,890.00. Following the completion of the sale, the insider now directly owns 19,569 shares in the company, valued at approximately $2,443,972.41. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Steven Mizell sold 50,694 shares of the stock in a transaction dated Friday, February 2nd. The shares were sold at an average price of $126.65, for a total value of $6,420,395.10. Following the sale, the executive vice president now owns 23,619 shares of the company’s stock, valued at $2,991,346.35. The disclosure for this sale can be found here. 0.20% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on MRK. TheStreet cut Merck & Co., Inc. from a “b+” rating to a “c+” rating in a research note on Monday, March 4th. TD Cowen upgraded Merck & Co., Inc. from a “market perform” rating to an “outperform” rating and raised their price target for the stock from $125.00 to $135.00 in a research report on Thursday, January 4th. Truist Financial reissued a “buy” rating and set a $142.00 price target (up from $139.00) on shares of Merck & Co., Inc. in a research note on Thursday, March 28th. Cantor Fitzgerald restated an “overweight” rating and set a $135.00 price objective on shares of Merck & Co., Inc. in a research report on Wednesday, March 27th. Finally, UBS Group lifted their target price on Merck & Co., Inc. from $135.00 to $148.00 and gave the stock a “buy” rating in a report on Friday, February 2nd. One investment analyst has rated the stock with a sell rating, four have given a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $129.71.

Get Our Latest Research Report on Merck & Co., Inc.

Merck & Co., Inc. Stock Performance

MRK stock traded up $0.50 during midday trading on Wednesday, hitting $130.85. The company’s stock had a trading volume of 2,273,934 shares, compared to its average volume of 8,614,414. The stock’s 50-day moving average price is $125.45 and its 200 day moving average price is $113.20. The company has a quick ratio of 1.00, a current ratio of 1.25 and a debt-to-equity ratio of 0.89. Merck & Co., Inc. has a 1 year low of $99.14 and a 1 year high of $133.10. The stock has a market cap of $331.40 billion, a price-to-earnings ratio of 931.07, a PEG ratio of 0.52 and a beta of 0.38.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last issued its quarterly earnings results on Thursday, February 1st. The company reported $0.03 EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.12. Merck & Co., Inc. had a return on equity of 9.33% and a net margin of 0.61%. The firm had revenue of $14.63 billion for the quarter, compared to analysts’ expectations of $14.49 billion. During the same quarter in the prior year, the firm earned $1.62 EPS. The business’s revenue for the quarter was up 5.8% compared to the same quarter last year. On average, equities analysts forecast that Merck & Co., Inc. will post 8.59 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 5th. Investors of record on Friday, March 15th will be paid a dividend of $0.77 per share. The ex-dividend date is Thursday, March 14th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 2.35%. Merck & Co., Inc.’s payout ratio is 2,200.00%.

Merck & Co., Inc. Company Profile

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

See Also

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKFree Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.